Viatris Inc — Director's Dealing 2020

Nov 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viatris Inc (VTRS)
CIK: 0001792044
Period of Report: 2020-11-16

Reporting Person: COURY ROBERT J (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	A	1383587	—	Acquired	1383587	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-16	Employee Stock Option - Right to Buy	$22.66	A	4413	Acquired	2021-03-02	Common Stock (4413)	Direct
2020-11-16	Employee Stock Option - Right to Buy	$23.44	A	4266	Acquired	2022-02-22	Common Stock (4266)	Direct
2020-11-16	Employee Stock Option - Right to Buy	$30.90	A	3236	Acquired	2023-03-06	Common Stock (3236)	Direct
2020-11-16	Employee Stock Option - Right to Buy	$55.84	A	58952	Acquired	2024-03-05	Common Stock (58952)	Direct
2020-11-16	Employee Stock Option - Right to Buy	$50.66	A	63235	Acquired	2025-11-17	Common Stock (63235)	Direct
2020-11-16	Employee Stock Option - Right to Buy	$46.27	A	82776	Acquired	2026-02-17	Common Stock (82776)	Direct
2020-11-16	Restricted Stock Units	$0.00	A	250000	Acquired		Common Stock (250000)	Direct

Footnotes

F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4: These options vested on March 2, 2014.

F5: These options vested on February 22, 2015.

F6: These options vested on March 6, 2016.

F7: These options vested on March 5, 2017.

F8: These options vested on March 4, 2018.

F9: These options vested on February 17, 2019.

F10: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F11: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on June 24, 2021.